**Publications in 2024**

**Publications in 2023**

1. Jørgensen CK, Olsen MH, Nielsen N, Lange T, Mbuagbaw L, Thabane L, Billot L, Binder N, Garattini S, Banzi R, Demotes J, Biagioli E, Rulli E, Bertolini G, Nattino G, Mathiesen O, Torri V, Gluud C, Jakobsen JC. Centre for Statistical and Methodological Excellence (CESAME): A Consortium Initiative for Improving Methodology in Randomised Clinical Trials. Health Services Insights. 2023;16:11786329231166519.
2. Hansen ML, Jørgensen CK, Thabane L, Rulli E, Biagioli E, Chiaruttini M, Mbuagbaw L, Mathiesen O, Gluud C, Jakobsen JC. Observed intervention effects for mortality in randomised clinical trials: a methodological study protocol. BMJ Open. 2023;13(6):e072550.
3. Granholm A, Møller MH, Gluud C, Lundh A, Hróbartsson A, de Muckadell OBS, Perner A. Critical reading of articles on randomised clinical trials. Ugeskrift for Laeger. 2023;185(45):V06230427.
4. Fraquelli M, Nadarevic T, Colli A, Manzotti C, Giljaca V, Miletic D, Stimac D, Casazza G. Contrast-enhanced ultrasound (CEUS) for the diagnosis of hepatocellular carcinoma (HCC) in adults with chronic liver disease. a cochrane systematic review and metanalysis. Hepatology. 2023;78(Suppl 1):S1916-7.

**Publications in 2022**

1. Riberholt CG, Olsen MH, Milan JB, Gluud C. Major mistakes and errors in the use of Trial Sequential Analysis in systematic reviews or meta-analyses - protocol for a systematic review. Systematic Reviews. 2022;11(1):114.
2. Malik AK, Amer AO, White SA, Manas DM, Wilson CH. Fibrin-based haemostatic agents for reducing blood loss in adult liver resection: a meta-analysis. British Journal of Surgery. 2022;109(SUPPL 4):O092.

**Publications in 2021**

1. Barbateskovic M, Koster TM, Eck RJ, Maagaard M, Afshari A, Blokzijl F, Cronhjort M, Dieperink W, Fabritius ML, Feinberg J, French C, Gareb B, Geisler A, Granholm A, Hiemstra B, Hu RX, Imberger G, Jensen BT, Jonsson AB, Karam O, Kong DZ, Korang SK, Koster G, Lai BY, Liang N, Lundstrom LH, Marker S, Meyhoff TS, Nielsen EE, Norskov AK, Munch MW, Risom EC, Rygard SL, Safi S, Sethi N, Sjovall F, Lauridsen SV, van Bakelen N, Volbeda M, van der Horst ICC, Gluud C, Perner A, Moller MH, Keus E, Wetterslev J. A new tool to assess Clinical Diversity In Meta-analyses (CDIM) of interventions. Journal of Clinical Epidemiology. 2021;135:29-41.
2. Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Stimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review. Digestive and Liver Disease. 2021;53:S36.
3. Colli A, Nadarevic T, Miletic D, Giljaca V, Mirella F, Stimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review. Journal of Hepatology. 2021;75:S491.
4. Jakobsen JC, Wetterslev J, Gluud C. Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research. BMJ Evidence-Based Medicine. 2021;26(3):127-30.
5. Nørskov AK, Lange T, Nielsen EE, Gluud C, Winkel P, Beyersmann J, de Uña-Álvarez J, Torri V, Billot L, Putter H, Wetterslev J, Thabane L, Jakobsen JC. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. BMJ Evidence-Based Medicine. 2021;26(3):121-6.

**Publications in 2020**

1. Varganova DL, Pavlov CS, Casazza G, Nikolova D, Gluud C. Letter to the Editor: Glucocorticosteroids for Alcohol-Associated Hepatitis. Hepatology. 2020;71(4):1524.
2. Claire R, Gluud C, Berlin I, Coleman T, Leonardi-Bee J. Using Trial Sequential Analysis for estimating the sample sizes of further trials: example using smoking cessation intervention. BMC Medical Research Methodology. 2020;20(1):284.
3. Lawson DO, Puljak L, Pieper D, Schandelmaier S, Collins GS, Brignardello-Petersen R, Moher D, Tugwell P, Welch VA, Samaan Z, Thombs BD, Nørskov AK, Jakobsen JC, Allison DB, Mayo-Wilson E, Young T, Chan AW, Briel M, Guyatt GH, Thabane L, Mbuagbaw L. Reporting of methodological studies in health research: a protocol for the development of the MethodologIcal STudy reportIng Checklist (MISTIC). BMJ Open. 2020 Dec 17;10(12):e040478.

**Publications in 2019**

* 1. Gartlehner G, Nussbaumer-Streit B, Wagner G, Patel S, Swinson-Evans T, Dobrescu A, Gluud C. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology. 2019;106:50-9.
  2. Jakobsen JC, Ovesen C, Winkel P, Hilden J, Gluud C, Wetterslev J. Power estimations for non-primary outcomes in randomised clinical trials. BMJ Open. 2019;9(6):e027092.
  3. Koretz RL, Jakobsen JC, Hauser G, Nikolova D, Gluud C. Letter to Editor: Response to AASLD Editorial/Message from the President. Hepatology. 2019;69(5):2300.
  4. Liang N, Kong DZ, Ma SS, Lu CL, Yang M, Feng LD, Liu XH, Gluud C, Liu JP. Error matrix tool to overview the validity of evidence on radix sophorae flavescentis for chronic hepatitis B. Journal of Alternative and Complementary Medicine. 2019;25(9):957-73.
  5. Nielsen EE, Norskov AK, Lange T, Thabane L, Wetterslev J, Beyersmann J, de Una-Alvarez J, Torri V, Billot L, Putter H, Winkel P, Gluud C, Jakobsen JC. Assessing assumptions for statistical analyses in randomised clinical trials. BMJ Evidence-Based Medicine. 2019;24(5):185-9.
  6. Pavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis (Cochrane review). Terapevticheskii Arkhiv. 2019;91(8):52-66.

**Publications in 2018**

1. Castellini G, Bruschettini M, Gianola S, Gluud C, Moja L. Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews. 2018;7(1):110.
2. Dam G, Aamann L, Vistrup H, Gluud LL. The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology. 2018;8(4):448-51.
3. Faltinsen EG, Storebo OJ, Jakobsen JC, Boesen K, Lange T, Gluud C. Network meta-analysis: the highest level of medical evidence? BMJ. 2018;23(2):56-9.
4. Jakobsen JC, Nielsen EE, Koretz RL, Gluud C. Do direct acting antivirals cure chronic hepatitis C? BMJ. 2018;361:k1382.
5. Koretz RL, Jakobsen JC, Djurisic S, Poropat G, Hauser G, Bjelakovic M, Bjelakovic G, Gluud C. Who is wrong? Responses to Kwo et al. American Journal of Gastroenterology. 2018;113(5):779-80.
6. Koretz RL, Jakobsen JC, Gluud C. Letter to the editor re: Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evidence-Based Medicine. 2018;23(6):240.
7. Liu J, Xue P, Deng J. Therapeutic effect of photodynamic therapy for nonresectable cholangiocarcinoma: Protocol for a meta-analysis and systematic review. Medicine (Baltimore). 2018;97(8):e9863.
8. Shokraneh F, Adams CE, Clarke M, Amato L, Bastian H, Beller E, Brassey J, Buchbinder R, Davoli M, Del Mar C, Glasziou P, Gluud C, Heneghan C, Hoffmann T, Ioannidis JPA, Jayaram M, Kwong J, Moher D, Ota E, Sheriff RS, Vale L, Ben Goldacre. Why Cochrane should prioritise sharing data. BMJ. 2018;362:k3542.

**Publications in 2017**

* 1. Afshari A, Wetterslev J, Smith AF. Can systematic reviews with sparse data be trusted? Anaesthesia. 2017;72(1):12-6.
  2. Castellini G, Nielsen EE, Gluud C. Comment on: "Cell Therapy for Heart Disease: Trial Sequential Analyses of Two Cochrane Reviews". Clinical Pharmacology & Therapeutics. 2017;102(1):21-4.
  3. Colli A, Fraquelli M, Prati D, Conte D, Casazza G. Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis. Digestive and Liver Disease. 2017;49(1):E22-3.
  4. Colli A, Fraquelli M, Prati D, Conte D, Casazza G. Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis. Journal of Hepatology. 2017;66(1):S120.
  5. Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, Hivert V, Neugebauer EAM, Laville M, Hiesmayr M, Demotes-Mainard J, Kubiak C, Jakobsen JC, Gluud C. Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 2017;18(1):360.
  6. Goh ET, Stokes CS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials. Journal of Hepatology. 2017;66(1):S131.
  7. Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Medical Research Methodology. 2017;17(1):162.
  8. Kimer N, Gluud LL, Morris RW, Morgan MY. Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials. Journal of Hepatology. 2017;66(1):S561-2.
  9. Ohmann C, Banzi R, Canham S, Battaglia S, Matei M, Ariyo C, Becnel L, Bierer B, Bowers S, Clivio L, Dias M, Druml C, Faure H, Fenner M, Galvez J, Ghersi D, Gluud C, Groves T, Houston P, Karam G, Kalra D, Knowles R. L, Krleza-Jeric K, Kubiak C, Kuchinke W, Kush R, Lukkarinen A, Marques PS, Newbigging A, O'Callaghan J, Ravaud P, Schlunder I, Shanahan D, Sitter H, Spalding D, Tudur-Smith C, van Reusel P, van Veen EB, Visser GR, Wilson J, Demotes-Mainard J. Sharing and reuse of individual participant data from clinical trials: principles and recommendations. BMJ Open. 2017;7(12):e018647.
  10. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology. 2017;17(1):39.

**Publications in 2016**

1. Dossing A, Tarp S, Furst DE, Gluud C, Wells GA, Beyene J, Hansen BB, Bliddal H, Christensen R. Modified intention-to-treat analysis did not bias trial results. Journal of Clinical Epidemiology. 2016;72:66-74.
2. Garattini S, Jakobsen JC, Wetterslev J, Bertele V, Banzi R, Rath A, Neugebauer EAM, Laville M, Masson Y, Hivert V, Eikermann M, Aydin B, Ngwabyt S, Martinho C, Gerardi C, Szmigielski CA, Demotes-Mainard J, Gluud C. Evidence-based clinical practice: Overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine. 2016;32:13-21.
3. Gluud LL, Vilstrup H, Morgan MY. Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology. 2016;64(3):908-22.
4. Imberger G, Thorlund K, Gluud C, Wetterslev J. False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review. BMJ Open. 2016;6(8):e011890.
5. Israelsen ME, Allegretti AS, Krag A, Jovani M, Goldin AH, Schulman A, Gluud LL. Vasoactive drugs for hepatorenal syndrome: a meta-analysis. Journal of Hepatology. 2016;64:S662.
6. Pavlov C, Casazza G, Nikolova D, Gluud C. Editorial: in vino veritas - transient elastography for staging liver fibrosis in alcoholic liver disease - authors' reply. Alimentary Pharmacology & Therapeutics. 2016;43(9):1015-6.
7. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Gluud C. Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Alimentary Pharmacology & Therapeutics. 2016;43(5):575-85.
8. Simillis C, Robertson FP, Afxentiou T, Davidson BR, Gurusamy KS. A network meta-analysis comparing perioperative outcomes of interventions aiming to decrease ischemia reperfusion injury during elective liver resection. Surgery. 2016;159(4):1157-69.

**Publications in 2015**

1. Afshari A, Wetterslev J. When may systematic reviews and meta-analyses be considered reliable? European Journal of Anaesthesiology. 2015;32(2):85-7.
2. Bjelakovic G, Nikolova D, Bjelakovic M, Gluud C. Vitamin d supplementation for chronic liver disease - a Cochrane Hepato-biliary Group systematic review. Journal of Hepatology. 2015;62:S837.
3. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Sao Paulo Medical Journal. 2015;133(2):164-5.
4. Buzzetti E, Kalafateli M, Thorburn D, Davidson B, Tsochatzis E, Gurusamy K. Pharmacological treatments for severe alcoholic hepatitis: a network meta-analysis. Journal of Hepatology. 2015;62:S773.
5. Giljaca V, Stimac D, Gluud C. Are levels of alkaline phosphatases and bilirubin surrogate markers of outcomes of patients with primary biliary cirrhosis? Gastroenterology. 2015;148(4):860.
6. Gluud L. L, Vilstrup H, Morgan MY. The effect of treatment for hepatic encephalopathy with nonabsorbable disaccharides on morbidity and mortality in patients with cirrhosis: systematic review and meta-analyses. Journal of Hepatology. 2015;62:S353.
7. Gurusamy K, Saffioti F, Toon C, Davidson B, Tsochatzis E, Thorburn D. Pharmacological treatments for primary sclerosing cholangitis: a network meta-analysis. Gut. 2015;64:A254-5.
8. Morris S, Gurusamy KS, Sheringham J, Davidson BR. Cost-effectiveness analysis of endoscopic ultrasound versus magnetic resonance cholangiopancreatography in patients with suspected common bile duct stones. PLOS One. 2015;10(3):e0121699.
9. Simillis C, Li TJ, Vaughan J, Becker LA, Davidson BR, Gurusamy KS. A Cochrane systematic review and network meta-analysis comparing treatment strategies aiming to decrease blood loss during liver resection. International Journal of Surgery. 2015;23:128-36.
10. Simillis C, Robertson FP, Afxentiou TC, Davidson BR, Gurusamy KS. The effectiveness of treatments for ischaemia reperfusion injury during liver resection surgery determined by network meta-analysis. British Journal of Surgery. 2015;102:20.
11. Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver International. 2015;35(8):2009-16.
12. Wetterslev J, Jakobsen JC, Gluud C. Forsøgssekventielle metaanalyser i systematiske oversigter. Bibliotek for Laeger 2015;207(2):124-51.

**Publications in 2014**

1. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology 2014, 14:120 doi:10.1186/1471-2288-14-120.
2. Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance – a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology 2014, 14:34 doi:10.1186/1471-2288-14-34.
3. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, Gluud C. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews 2014, Issue 6. Art. No.: CD007469. DOI: 10.1002/14651858.CD007469.pub2.
4. Nikolova D, Gluud C. CHBG Newsletter. 2014;18(2):1-14.
5. Nikolova D, Gluud C. CHBG Newsletter. 2014;18(1):1-6.
6. Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. Current Opinion in Clinical Nutrition and Metabolic Care. 2014;17(1):40-4.

**Publications in 2013**

1. Nikolova D, Gluud C. CHBG Newsletter. 2013;17(2):1-14.
2. Nikolova D, Klingenberg SL, Gluud C. The Cochrane Hepato-Biliary Group as a resource example of evidence-based medicine for all. Acta Medica Portuguesa 2013;26(2):81-2.
3. Nikolova D, Gluud C. CHBG Newsletter. 2013;17(1):1-14.
4. Strandbygaard J, Bjerrum F, Maagaard M, Winkel P, Larsen CR, Ringsted C, et al.·Instructor feedback versus no Instructor feedback on performance in a laparoscopic virtual reality simulator: a randomized trial.·Annals of Surgery. 2013;257(5):839-44.
5. Colli A, Fraquelli M, Casazza G, Conte D, Nikolova D, Duca P, Thorlund K, Gluud C. The architecture of diagnostic research: From bench to bedside - clinical guidelines using liver stiffness as an example. Hepatology. 2013; Nov 26. doi: 10.1002/hep.26948. [Epub ahead of print].
6. Thiele M, Wiest R, Gluud LL, Albillos A, Krag A. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses. 2013;81(5):871-4.
7. Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements to prevent mortality. JAMA. 2013;310(11):1178-9.
8. Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? PLoS One. 2013;8(9):e74558.
9. Firwana B, Ferwana M, Hasan R, Alpert MA, Faries P, Dangas G, Gluud C. Open versus endovascular stent graft repair of abdominal aortic aneurysms: Do we need more randomized clinical trials? Angiology. 2013 Sep 3. [Epub ahead of print].
10. Imberger G, Wetterslev J, Gluud C. Trial sequential analysis has the potential to improve the reliability of conclusions in meta-analysis. Contemp Clin Trials. 2013;36(1):254-5.
11. Liu JP, Han M, Li XX, Mu YJ, Lewith G, Wang YY, Witt CM, Yang GY, Manheimer E, Snellingen T, Berman B, Gluud C. Prospective registration, bias risk and outcome-reporting bias in randomised clinical trials of traditional Chinese medicine: an empirical methodological study. BMJ Open. 2013;3(7). doi:pii: e002968.
12. Nikolova D, Klingenberg SL, Gluud C. The Cochrane hepato-biliary group as a resource example of evidence-based medicine for all. Acta Med Port. 2013;26(2):81-2.
13. Martí-Carvajal A, Gluud C. Effectiveness of human recombinant activated protein C for severe sepsis and septic shock in adult and pediatric patients: randomized clinical trial versus nonrandomized study. Crit Care Med. 2013;41(7):e139.
14. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Risum N, Vilstrup H. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013;143(8):1263-8.
15. Bai M, Qi X, Yang M, Han G, Fan D. Combined-therapies vs. monotherapies for the first variceal bleeding in patients with high-risk varices: a meta-analysis of RCTs. J Gastroenterol Hepatol. 2013. doi: 10.1111/jgh.12396. [Epub ahead of print].
16. Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, Gluud C. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention? PLoS One. 2013 Dec 12;8(12):e83313. doi: 10.1371/journal.pone.0083313.

**Publications in 2012**

* 1. Nikolova D, Gluud C. CHBG Newsletter. 2012;16(2):1-10.
  2. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, A Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment. 2012 Sep;16(35):1-82.
  3. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, A Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JA. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine. 2012;157(6):429-38.
  4. Oliveri RS, Wetterslev J, Gluud C. Hepatocellular carcinoma. Lancet. 2012;380(9840):470; author reply 470-1.
  5. Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, Gluud C, Devereaux PJ, Wetterslev J. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One. 2012;7(7):e39471.
  6. Penninga L, Wettergren A, Steinbruchel DA, Wilson CH, Gluud C. Interleukin-2 receptor antagonists for liver transplant recipients: Systematic review with meta-analyses and trial sequential analyses of randomised trials. Journal of Hepatology. 2012;56(Suppl 2):S92.
  7. Nikolova D, Gluud C. CHBG Newsletter. 2012;16(1):1-10.

**Publications in 2011**

1. Nikolova D, Gluud C. CHBG Newsletter. 2011;15(2):1-9.
2. Jianping Liu. (2011).Terminology of Evidence-Based Medicine (1st ed.). Beijing: Academy Press. [in Chinese]
3. Nikolova D, Gluud C. CHBG Newsletter. 2011;15(1):1-12.
4. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Design of surgical randomized controlled trials involving multiple interventions. Journal of Surgical Research 2011;165(1):118-27.
5. Imberger G, Gluud C, Wetterslev J. Comments on 'Sequential methods for random-effects meta-analysis'. Statistics in Medicine 2011;20(24):2965-6.
6. Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, Guyatt G, Devereaux PJ, Thabane L. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis - a simulation study. PLOS One 2011;6(10):e25491.
7. Dal-Re R, Moher D, Gluud C, Treweek S, Demotes-Mainard J, Carne X. Disclosure of investigators' recruitment performance in multicenter clinical trials: A further step for research transparency. PLOS Medicine 2011,8(12):e1001149.
8. Bjelakovic G, Gluud C. Vitamin and mineral supplement use in relation to all-cause mortality in the Iowa Women's Health Study. Archives of Internal Medicine 2011;171(18):1633-4.
9. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Antibiotic prophylaxis during bleeding for portal hypertension: auhtors' reply. Alimentary Pharmacology & Therapeutics 2011;34(8):1033-4.
10. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane Review. Alimentary Pharmacology & Therapeutics 2011;34(5):509-18.
11. Awad T, Thorlund K, Auser G, Stimac D, Mabrouk M, Gluud C. "Real-life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus reply. Hepatology 2011;53(4):1407.

**Publications in 2010**

* 1. Nikolova D, Gluud C. CHBG Newsletter. 2010;14(2):1-6.
  2. Whitfield K, Huemer KH, Winter D, Thirstrup S, Libersa C, Barraud B, et al. Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials. 2010;12(11):104.
  3. Klingenberg SL, Nikolova D, Alexakis N, Als-Nielsen B,Colli A, Conte D, et al. Hepato-biliary clinical trials and their inclusion in the Cochrane Hepato-Biliary Group register and reviews. Journal of Gastroenterology and Hepatology 2010; DOI: 10.1111/j.1440-1746.2010.06465.x.
  4. Thorlund K, Imberger G, Wetterslev J, Brok J, Gluud C. Comments on 'Sequential meta-analysis: an efficient decision-making tool' by I van der Tweel and C Bollen. Clinical Trials 2010;7(6):752-3; author reply 754.
  5. Keus F, Wetterslev J, Gluud C, van Laarhoven CJ. Evidence at a glance: error matrix approach for overviewing available evidence. BMC Medical Research Methodology 2010;10:90.
  6. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51(4):1176-84.
  7. Krag A, Wiest R, Gluud LL. Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis. American Journal of Gastroenterology 2010;105(6):1444; author reply 1444-5.
  8. Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Alimentary Pharmacology and Therapeutics 2010;32(7):859-71.
  9. Brok J, Gluud LL, Gluud C. Meta-analysis: ribavirin plus interferon vs. interferon monotherapy for chronic hepatitic C - an updated Cochrane review. Alimentary Pharmacology and Therapeutics 2010;32(7):840-50.
  10. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver diseases - the Cochrane Hepato-Biliary Group. Alimentary Pharmacology and Therapeutics 2010;32(3):356-67.
  11. Krag A, Wiest R, Gluud LL. Endoscopic variceal ligation alone or with pharmacological therapy for recurrent variceal bleeding: the importance of intention-to-treat analyses. Alimentary Pharmacology and Therapeutics 2010;31(2):341-3. Comment on: Alimentary Pharmacology and Therapeutics 2009;30(6):577-88.
  12. Brok J, Gluud C. [Comment of the paracetamol debate - next step][Article in Danish]. Ugeskrift for Laeger 2010;172(21):1623; author reply 1623.
  13. Gurusamy K, Samraj K, Gluud C, Wilson E, Davidson BR. Meta-analysis of randomized controlled trials on the safety and effectiveness of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. British Journal of Surgery 2010;97(2):141-50. Erratum in: British Journal of Surgery 2010;97(4):624.
  14. Wilson E, Gurusamy K, Gluud C, Davidson BR. Cost-utility and value-of-information analysisof early versus delayed laparoscopic cholecystectomy for acute cholecystitis. British Journal of Surgery 2010;97(2):210-9.
  15. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Trial sequential analyses of meta-analyses of complications in laparoscopic vs. small-incision cholecystectomy: more randomized patients are needed. Journal of Clinical Epidemiology 2010;63(3):246-56.
  16. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51(2):576-84.
  17. Nikolova D, Gluud C. CHBG Newsletter. 2010;14(1):1-6.

**Publications in 2009**

* 1. Nikolova D, Gluud C. CHBG Newsletter 2009;13(2):1-8.
  2. Awad T, Thorlund K, Mabrouk M, Gluud C. Hepatitis C intervention research - Where are we now and where should we be heading? Arab Journal of Gastroenterology 2009;10:4-9.
  3. Gluud LL, Langholz E, Krag A. Isosorbide mononitrate for patients with esophageal varices: systematic review of randomized trials on primary or secondary prevention. Hepatology. 2009;50(4 Suppl):439A.
  4. Gluud LL, Christensen K, Christensen E, Krag A. Vasoactive drugs for hepatorenal syndrome: systematic review and meta-analysis of randomized trials. Hepatology. 2009;50(4 Suppl):469A.
  5. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2A may achieve higher sustained virological response than peginterferon alpha-2B in chronic hepatitis C: a Cochrane Systematic Review of randomised clinical trials. Hepatology. 2009; 50(4 Suppl):707A.
  6. Gluud LL, Rask-Madsen J. Gastroenterology. In: Gad SC, ed. Clinical Trials Handbook. Publisher:John Wiley & Sons, Inc. 2009;501-17.
  7. Gluud LL, Gluud C. Meta-analyses on viral hepatitis. Infectious Disease Clinics of North America. 2009;23(2):315-30.
  8. Gluud C, Hilden J. Povl Heiberg's 1897 methodological study on the statistical method as an aid in therapeutic trials. Preventive Medicine. 2009;48(6):600-3.
  9. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. Assessment of risk of bias in randomized clinical trials in surgery. The British Journal of Surgery. 2009;96(4):342-9.
  10. Koretz RL, Gluud C. Prolonged therapy for hepatitis C with low-dose peginterferon. New England Journal of Medicine. 2009;360(11):1151; author reply 1152-3.
  11. Tsochatzis EA, Gurusamy KS, Gluud C, Burroughs AK. Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. Journal of Hepatology 2009;51(6):1084-5.
  12. Keus F, Wetterslev J, Gluud C, Gooszen HG, van Laarhoven CJ. Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. American Journal of Gastroenterology. 2009;104(3):546-51.
  13. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9(1):86.
  14. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? International Journal of Epidemiology. 2009;38(1):276-86.
  15. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology. 2009;38(1):287-98.
  16. Nikolova D, Gluud C. CHBG Newsletter 2009;13(1):1-6.

**Publications in 2008**

* 1. Nikolova D, Gluud C. CHBG Newsletter 2008;12(2):1-7.
  2. Gluud C, Nikolova. Evidence-based clinical practice and the Cochrane Hepato-Biliary Group. Acta Fac Med Naiss 2008;25(3):145-9.
  3. Brok J. Evaluation of and agreement between Cochrane neonatal reviews and clinical practice guidelines for newborns in Denmark. Ph.D. Thesis. University of Copenhagen, Faculty of Health Sciences; 2008:1-39.
  4. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Systematic review and meta-analysis: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Alimentary Pharmacology & Therapeutics. 2008;28(6):689-703.
  5. Møller CH, Penninga L, Wetterslev J, Steinbrüchel DA, Gluud C. Clinical outcomes in randomized trials of off- vs. on-pump coronary artery bypass surgery: systematic review with meta-analyses and trial sequential analyses. European Heart Journal. 2008;29(21):2601-16.
  6. Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Interleukin-2 receptor antagonists as induction therapy after heart transplantation: systematic review with meta-analysis of randomized trials. The Journal of Heart and Lung Transplantation. 2008 (8):835-42.
  7. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Alimentary Pharmacology & Therapeutics. 2008;27(12):1167-78.
  8. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.
  9. Gluud C, Dejgaard A, Krams M, Wallenbeck I, Tougas G, Wetterslev J, et al. International symposium on adaptive clinical trial designs. Drug Information Journal 2008;42(1):93-7.
  10. Gluud LL, Klingenberg SL, Langholz SE. Systematic review: tranexamic acid for upper gastrointestinal bleeding. Alimentary Pharmacology & Therapeutics. 2008;27(9):752-8.
  11. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology. 2008;61(1):64-75.
  12. Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008:2;111(4):280-7.
  13. Gandhi GY, Murad H, Flynn DN, Erwin PJ, Cavalcante AB, Nielsen HB, Capes SE, Thorlund K, Montori VM, Devereaux PJ. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomised trials. Mayo Clinic Proceedings 2008;83(4):418-30.
  14. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
  15. Koretz RL. Comment on: Early enteral supplementation with key pharmaconutrients improves sequential organ failure assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. Nutrition in Clinical Practice 2008, 23:447-9.
  16. Nikolova D, Gluud C. CHBG Newsletter 2008;12(1):1-9.

**Publications in 2007**

1. Nikolova D, Gluud C. CHBG Newsletter 2007;11(2):1-8.
2. Winkel P, Zhang NF. Statistical development of quality in medicine. Publisher: John Wiley & Sons Ltd, 2007. ISBN:978-0-470-02777-6.
3. Gluud C, on behalf of the Cochrane Hepato-BiliaryGroup. In: Juan Rodès, Jean-Pierre Benhamou, Andres T Blei, Jürg Reichen, M Rizzetto, ed. Textbook of Hepatology. Vol. 1. Publisher:Oxford.Blackwell Publishing Ltd 2007; 572-9.
4. Gong Y. Interventions for patients with primary biliary cirrhosis: systematic reviews and meta-analyses of randomised clinical trials. Ph.D. Thesis. University of Copenhagen, Faculty of Health Sciences; 2007:1-55.
5. Gong Y, Klingenberg L, Gluud C. D-penicillamine vs placebo/no intervention in patients with primary biliary cirrhosis. Evidence-Based Gastroenterology 2007;8(2):41-2.
6. Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable modelling for meta-epidemiological assessment of the association between trial quality and treatment effects estimated in randomized clinical trials. Statistics in Medicine 2007;26(14):2745-58.
7. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using bayesian approach as sensitivity analyses. American Journal of Gastroenterology 2007;102:1799-1807.
8. Bjelakovic G, Gluud C. Surviving antioxidant supplements. Journal of the National Cancer Institute 2007;99:742-3.
9. Nikolova D, Gluud C. The CHBG's Newsletter 2007;11(1):1-9.
10. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs interferon plus ribavirin forchronic hepatitis C. Alimentary Pharmacology & Therapeutics 2007;25:1153-62.
11. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734-42.
12. Bjelakovic G, Nikolova D, Gluud LL,Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297(8):842-57.
13. Gluud C, Nikolova D. Likely country of origin in publications on randomised controlled trials and controlled clinical trials during the last 60 years. Trials. 2007;8:7.
14. Yan G, Erik C, Gluud C. The long-term beneficial effects of ursodeoxycholicacid in primary biliary cirrhosis are highly questionable. American Journal of Gastroenterology 2007;102(2):464-5.
15. Gong Y, Klingenberg SL, Gluud C. Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis. Alimentary Pharmacology & Therapeutics. 2006;24(11-12):1535-44.
16. Brok J, Greisen G, Jacobsen T, Gluud LL, Gluud C. Agreement between Cochrane Neonatal Group reviews and clinical guidelines for newborns at a Copenhagen University Hospital - a cross-sectional study. Acta Paediatrica 2007;96(1):39-43.
17. Nikolova D, Gluud C. CHBG Newsletter 2007;11(1):1-9.

**Publications in 2006**

1. Nikolova D, Gluud C. CHBG Newsletter 2006;10(2):1-8.
2. Bjelakovic G, Nagorni A, Nikolova D, Simonetti RG, Bjelakovic M, Gluud C. Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Alimentary Pharmacology & Therapeutics 2006;24(2):281-91.
3. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. 243 antioxidant supplements for prevention of liver cancer. Journal of Hepatology 2006;44(Suppl 2):S97-S98.
4. Brok J, Gluud L L, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. American Journal of Gastroenterology 2006;101(4):842-7.
5. Gluud C. The culture of designing hepato-biliary randomised trials. Journal of Hepatology 2006;44(1):607-15.
6. Nikolova D, Gluud C. The CHBG's Newsletter 2006;10(1):1-8.
7. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163(6):493-501.
8. Gluud LL. Unravelling industry bias in clinical trials. Pain 2006 Apr;121(3):175-6.
9. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C; en nombre del grupo de Ottawa. [Principles of the international registry of protocols and clinical trial results based on health interventions in human beings: Ottawa Declaration (part 1)]. Revista Panamericana Salud Publica 2006 Jun;19(6):413-6.
10. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud, LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation a meta-analysis. American Journal of Transplantation 2006;6(7)1578-85.
11. Gong Y, Klingenberg SL, Gluud C. D-penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis: Cochrane Hepato-Biliary Group systematic review with meta-analyses of randomised clinical trials. Alimentary Pharmacology & Therapeutics 2006;24:1535-44.
12. Kjellberg PK. Klinisk praksisvariation og kliniske retningslinjer. [Differences in clinical practice and clinical guidleines.]. Ph.D. Thesis (in Danish) DSI report 2006.10. (www.dsi.dk)
13. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ (Clinical Research Ed.) 2006;332(7537):328-36.
14. Nikolova D, Gluud C. The CHBG's Newsletter 2006;10(2):1-8.
15. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C a Cochrane Hepato-biliary Group systematic review. 4th Congress of the Croatian Society of Gastroenterology', Zagreb, Croatia. 2006:p.24.
16. Wille-Jorgensen P, Gluud C. Prospective registration of clinical trials. Colorectal Disease 2006;8(1)1.
17. Gluud C, Klingenberg SL, Gluud LL. Quality of Randomised Clinical Trials in Portal Hypertension and Other Fields of Hepatology. In: Roberto De Franchis, ed. Portal hypertension IV. 1st ed.Publisher: Oxford.Blackwell Publishing Ltd 2006.328-344.
18. Nikolova D, Gluud C. CHBG Newsletter 2006;10(1):1-8.

**Publications in 2005**

1. Nikolova D, Gluud C. The CHBG's Newsletter 2005;9(2):1-6.
2. Als-Nielsen BE, Gluud LL, Gluud CN. [Nonabsorbable disaccharides for the treatment of hepatic encephalopathy - a systemic review of randomized clinical trials - a secondary publication]. Ugeskrift for Læger 2005;167(2):179-82.
3. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers [letter]. Lancet 2005;365(9458):471-2.
4. Gluud C, Gluud LL. Evidence based diagnostics. BMJ (Clinical Research Ed.) 2005;330(7493):724-6.
5. Gluud C. [Danish clinical intervention research-can it be done better?] Ugeskrift for Læger 2005;167(9):1003.
6. Kürstein P, Kjellberg J, Herbild L, Olsen KR, Willemann M, Søgaard J, Gluud C. Fra forskning til praksis [From research into practice] DSI Institut for Sundhedsvæsen [DSI Institute for Health Services Research]. DSI rapport 2005.01.
7. Gluud C. Mortality from cirrhosis: lack of progress over the last 35 years. Gut 2005;54(11):1523-6.
8. Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection. Archives of Internal Medicine 2005;165:1-7.
9. Gluud LL, Sørensen TI, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepatobiliary randomized clinical trials. American Journal of Gastroenterology 2005;100(11):2431-5.
10. Gluud LL. Bias in clinical intervention research. Doctoral Dissertation. Faculty of Health Sciences. 2005. København: Eget forlag 2005:3-32. Defended 19 August 2005 at the Copenhagen University.
11. Gong Y, Christensen E, Gluud C. Primary biliary cirrhosis. New England Journal of Medicine 2005;353(25):2719-20.
12. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. American Journal of Gastroenterology 2005;100:1876-85.
13. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ (Clinical Research Ed.) 2005;330(7497):956-8.
14. Kürstein P, Gluud LL, Willemann M, Olsen KR, Kjellberg J, Søgaard J, et al. Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. Journal of Hepatology 2005;43(6):984-9.
15. Kürstein P, Kjellberg J, Søgaard J, Gluud C. [How will the treatment of patients with liver diseases become evidence-based?]. Ugeskrift for Læger 2005;167(38):3610-1.
16. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane Hepato-Biliary Group review with meta-analyses of randomized clinical trials. American Journal of Gastroenterology 2005;100(11):2583-91.
17. Simin M, Brok J, Stimac D, Gluud LL, Gluud C. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C: Cochrane Hepato-Bilairy Group systematic review. Digestive Disease and Sciences 2005; 50(10):193.
18. Thorlund K, Wetterslev J. Heterogeneity sample size correction factor for meta-analyses. [abstract] In: Program & Abstract Book. 13th Cochrane Colloquium 2005;(October 22 - 26):146 (P141).
19. Gluud C. Evidence-based medicine, the Cochrane Collaboration and systematic reviews. Arab Journal of Gastroenterology 2005;6;(2):91-112.
20. Nikolova D, Gluud C. CHBG Newsletter 2005;9(1):1-5.

**Publications in 2004**

1. Nikolova D, Gluud C. CHBG Newsletter 2004;8(2):1-7.
2. Als-Nielsen B, Chen W, Gluud LL, Siersma V, Hilden J, Gluud C. Are trial size and reported methodological quality associated with treatment effects? Observational study of 523 randomised trials. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):102-3.
3. Als-Nielsen B, Gluud LL, Gluud C. Methodological quality and treatment effects in randomised trials: a review of six empirical studies. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):88-9.
4. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ (Clinical Research Ed.) 2004;328(7447):1046.
5. Als-Nielsen BE, Chen W, Gluud CN, Gluud LL. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?] Ugeskrift for Læger 2004;166(18):1676-8.
6. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers - a systematic review and meta-analysis. Lancet 2004;364:1219-28.
7. Brok J, Gluud C, Greisen G. Comparison of The Cochrane Neonatal Group Systematic Reviews and Danish guidelines for newborns. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):128.
8. Gluud C. Evidence-based medicine, The Cochrane Collaboration, and systematic reviews. In: 'Train the Trainers'. Crete 2004. [contents 50 pages] [CD-ROM Copyright OMGE/OMED 2004].
9. Gluud LL, Kürstein P, Kjellberg J, Olsen K, Willemann M, Søgaard J, Gluud C. The size of the gap between research evidence and clinical practice: questionnaire survey on treatment of patients with liver disease. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):129.
10. Gong Y, Frederiksen S, Gluud C. D-penicillamine for primary biliary cirrhosis: a systematic review of randomised clinical trials. [abstract] Proceedings of The Third Asian-Pacific Conference on Evidence-Based Medicine 2004;(November 26 - 28).
11. Hrobjartsson A, Forfang E, Haahr M, Als-Nielsen B, Stig B. Testing the success of blinding in randomised clinical trials. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):138-9.
12. Kürstein P. Fra klinisk forskning til klinisk praksis (og tilbage igen). [From clinical research to clinical practice and back again]. Nyhedsbrev [Newsletter]:2004;May:27-8.
13. Liu J, Manheimer E, Shi Y, Gluud C. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. Journal of Alternative & Complementary Medicine 2004;10(6):1041-51.
14. Oliveri RS, Gluud C, Wille-Jørgensen PA. [Physicians' skills with evidence-based medicine. Concepts, information retrieval and use.] Ugeskrift for Læger 2004;166(45):4040-3. Comment in: Ugeskrift for Læger 2004;166(50)4622; author reply 4622-3.
15. Oliveri RS, Gluud C, Wille-Jørgensen PA. Hospital doctors' self-rated skills in and use of evidence-based medicine - a questionnaire survey. Journal of Evaluation in Clinical Practice 2004;10(2):219-26.
16. Siersma V, Als-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariate modeling for meta-epidemiological assessment of the association between trial quality and apparent treatment effects in randomised clinical trials. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):91-2.
17. Wood L, Jüni P, Kjaergard L, Moher D, Royle P, Schulz K, et al. Trends in reported allocation concealment in RCTs included in systematic reviews. In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):207-8.
18. Wood L, Sterne J, Jüni P, Kjaergard L, Moher D, Royle P, et al. A combined database for meta-epidemiological research: characteristics of included trials. [abstract] In: Program & Abstract Book. 12th Cochrane Colloquium 2004;(October 2 - 6):206-7.
19. Nikolova D, Gluud C. CHBG Newsletter 2004;8(1):1-8.

**Publications in 2003**

1. Nikolova D, Gluud C. CHBG Newsletter 2003;7(2):1-8.
2. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials. A reflection of treatment effects or adverse events? JAMA 2003;290:921-8.
3. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003;124:1277-91.
4. Demicheli V, Tiberti D. The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine 2003;21:2242-5.
5. Gluud C. Evidence-based medicine, The Cochrane Collaboration, and systematic reviews. In: 'Train the Trainers'. New Zealand 2003. [contents 50 pages] [CD-ROM Copyright OMGE/OMED 2003].
6. Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage: a systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics 2003;17(1): 53-64.
7. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289(2):217-22.
8. Liu JP, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane Hepato-Biliary Systematic Review of randomized trials. The American Journal of Gastroenterology 2003; 98(3):538-44.
9. Soares-Weiser K, Brezis M, Tur-Kaspa R, Paul M, Yahav J, Leibovici L. Antibiotic prophylaxis of bacterial infections in cirrhotic patients: a meta-analysis of randomized controlled trials. Scandinavian Journal of Gastroenterology 2003;38(2):193-200.
10. Nikolova D, Gluud C. CHBG Newsletter 2003;7(1):1-5.

**Publications in 2002**

1. Nikolova D, Gluud C. CHBG Newsletter 2002;6(2):1-8.
2. Gluud C, Wang J. History of evidence based medicine. In Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;2-4.
3. Gluud C. Acute, serious drug-induced liver injury [Editorial]. Journal of Hepatology 2002;37(5):675-7.
4. Gluud C. Endocrine system. In: Sherman DIN, Preedy VR, Watso RR, eds. Ethanol and the liver. Mechanisms and management. Publisher: Taylor and Francis 2002;472-94.
5. Gluud C. Evidence based medicine, The Cochrane Collaboration, and systematic reviews. Organisation Mondiale de Gastro-Entérologie (OMGE)/Organisation Mondiale d'Endoscopie Digestive (OMED) Train the Trainers, Crete 2002 [Review on CD-ROM]. 2002;1-50.
6. Gluud C. Evidence-based medicine in hepato-biliary diseases. Chinese Hepatology 2002;7(suppl):21-6.
7. Gluud C. The Cochrane Hepato-Biliary Collaborative Review Group: achievements and challenges. Abstracts for The Second Asian-Pacific Conference on Evidence-Based Medicine 2002 (April 8-10):4-5.
8. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ (Clinical Research Ed.) 2002;325(7358):249.
9. Kjaergard LL, Frederiksen SL, Gluud C. Validity of randomized clinical trials in Gastroenterology from 1964 to 2000. Gastroenterology 2002;122(4):1157-60.
10. Kjaergard LL, Gluud C. Citation bias of hepato-biliary randomized clinical trials. Journal of Clinical Epidemiology 2002;55:407-10.
11. Kjaergard LL, Gluud C. Funding, disease area, and internal validity of hepatobiliary randomized clinical trials. The American Journal of Gastroenterology 2002;97(11):2708-13.
12. Kjaergard LL, Gluud C. Health technology assessment. In: Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;229-31.
13. Kjaergard LL, Liu J, Gluud C. How to assess the quality of evidence on intervention effects. In: Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;55-61.
14. Koretz RL. Is alternative medicine alternative science? Journal of Laboratory and Clinical Medicine 2002;139(6):329-33.
15. Koretz RL. Methods of meta-analysis: an analysis. Current Opinion in Clinical Nutrition and Metabolic Care 2002;5:467-74.
16. Liu J, Gluud C. Funnel plot analyses. In Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;118-21.
17. Liu J, Gluud C. Graphical presentation of the results of meta-analyses. In: Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;112-7.
18. Liu J, Kjaergard LL, Als-Nielsen B, Gluud C. A systematic review on extracorporeal liver support for liver failure. Journal of Hepatology 2002;36(suppl1):33.
19. Liu J, Kjaergard LL, Gluud C. Steps and methods of performing systematic reviews. In: Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;61-73.
20. Liu J, Liu X, Qian D, Lin H. Glycyrrhizin for chronic hepatitis: protocol of systematic review of randomized controlled trial. Abstracts for The Second Asian-Pacific Conference on Evidence-Based Medicine 2002 (April 8-10):54-5.
21. Liu J, McIntosh H, Gluud C. An example of a systematic review. In: Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002; 75-85.
22. Liu J, Qin X, Melchart D. Research priorities in traditional Chinese medicine: a questionnaire survey. Abstracts for The Second Asian-Pacific Conference on Evidence-Based Medicine 2002(April 8-10):31-2.
23. Liu J, Yang M. Alternative therapies for viral hepatitis in Chinese textbook of infectious diseases: What is the evidence? Abstracts for The Second Asian-Pacific Conference on Evidence-Based Medicine 2002 (April 8-10):61-2.
24. Liu JP, Kjaergard LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. Liver 2002;22(5):433-8.
25. Liu JP, Kjaergard LL, Gluud C. Misuse of randomization: a review on Chinese randomized trials of herbal medicines for chronic hepatitis B. The American Journal of Chinese Medicine 2002;30(1):173-6.
26. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane review. American Journal of Gastroenterology 2002;97(7):1674-81.
27. Soares-Weiser K, Paul M, Brezis M, Leibovici L. Antibiotic treatment for spontaneous bacterial peritonitis. BMJ (Clinical Research Ed.) 2002;324(7329):100-2.
28. Wang J, Gluud C, eds. Evidence-based medicine and clinical practice. Science Publisher: Beijing 2002;1-339.
29. Nikolova D, Gluud C. CHBG Newsletter 2002;6(1):1-6.

**Publications in 2001**

1. Nikolova D, Gluud C. CHBG Newsletter 2001;5(2):1-6.
2. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis: lessons for the future [Letter]. Journal of Hepatology 2001;34(5):787-8.
3. Gluud C, Kjærgard LL. Quality of randomised clinical trials in portal hypertension and other fields of hepatology. De Franchis R [editor]. Proceedings of the third Baveno International Consensus Workshop on definitions, methodology and therapeutic strategies. Portal Hypertension III. Oxford: Blackwell Science, 2001:204-18.
4. Gluud C. Alcoholic hepatitis: no glucocorticosteroids. In Steatohepatistis (NASH and ASH) - Falk Symposium 121. Leuschner U, James O, Dancygier H, eds. Kluwer Academic Publishers: Dordrecht. 2001:322-42.
5. Gluud C. Evidence-based medicine, The Cochrane Collaboration, and systematic reviews. In 'Train the Trainers'. Crete 2001. [contents 50 pages] [CD-ROM Copyright OMGE/OMED 2001].
6. Jefferson T, Demicheli V, Deeks J, MacMillan A, Sassi F, Pratt M. Vaccines for preventing hepatitis B in health care workers. Nursing Times 2001;97(46):39.
7. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for interferon naïve patients, relapsers, and non-responders with chronic hepatitis C: systematic review of randomised trials. BMJ (Clinical Research Ed.) 2001;323:1151-5.
8. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
9. Koretz RL, Lipman TO, Klein S. AGA Technical Review on Parenteral Nutrition. Gastroenterology 2001;121:970-1001.
10. Liu JP, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. Journal of Viral Hepatitis 2001;8(5):358-66.
11. Pedersen T, Gluud C, Gøtzsche P, Matzen P, Wille-Jørgensen PA. Hvad er evidensbaseret medicin? (What is evidence-based medicine?) Ugeskrift for Læger 2001;163:3769-72.
12. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 2001;21:129-36.
13. Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: a systematic review. Liver 2001;21:280-6.
14. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. Liver 2001;21(6):398-404.
15. Sørensen TIA, D'Amico G, van Buuren H, Gluud C, Kamath P, Riggio O, et al. Methodology of future trials: prognostic stratification, health-related quality of life, and health economics.
16. 3rd Baveno International Consensus Workshop. Portal Hypertension into the Third Millennium. Definition, Methodology and Therapeutic Strategies in Portal Hypertension. de Francis R, ed. Blackwell Science: Oxford. 2001;219-37.
17. Sørensen TIA, D'Amico G, van Buuren H, Gluud C, Kamath P, Riggio O, et al. Baveno III Consensus Statements: Methodologic requirements for future trials. 3rd Baveno International Concensus Workshop. Portal Hypertension into the Third Millennium. Definition, Methodology and Therapeutic Strategies in Portal Hypertension. de Francis R, ed. Blackwell Science: Oxford. 2001;238-9.
18. Nikolova D, Gluud C. CHBG Newsletter 2001;5(1):1-6.

**Publications in 2000**

1. Nikolova D, Gluud C. CHBG Newsletter 2000;4(2):1-4.
2. Frederiksen SL, Gluud C, Kjaergaard LL. Methodological quality and sample size of randomised trials published in 'Gastroenterology'. [abstract and poster presentation] 8th International Cochrane Colloquium 2000, Cape Town, South Africa.
3. Gluud C, Jørgensen T. Cochrane Hepato-Biliære Gruppe - status efter tre år. [The Cochrane Hepato-Biliary Group - three years later.] Ugeskrift for Læger 2000;162(21):3017-9.
4. Nikolova D, Gluud C. CHBG Newsletter 2000;4(1):1-6.

**Publications in 1999**

1. Nikolova D, Gluud C. CHBG Newsletter 1999;3(2):1-4.
2. Gluud C. Evidence based medicine in LIVER. Liver 1999;19:1-2.
3. Gluud C. The Cochrane Hepato-Biliary Group. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto M, Rodes J (eds). Oxford Textbook of Clinical Hepatology, 2nd edition. Oxford Medical Publications 1999:2145-8.
4. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in Hepatology: predictors of quality. Hepatology 1999;30(5):1134-8.
5. Nikolova D, Gluud C. CHBG Newsletter 1999;3(1):1-9.

**Publications in 1998**

1. Nikolova D, Gluud C. CHBG Newsletter 1998;2(2):1-4.
2. Gluud C, Nikolova D. Quality assessment of reports on clinical trials in Journal of Hepatology. Journal of Hepatology 1998;29:321-7.
3. Gluud C. The Cochrane Hepato-Biliary Group: a year later. Nordic Newsletter on Evidence-Based Health Care 1998;2:19-20.
4. Gluud C. 'Negative trials' are positive [editorial]. Journal of Hepatology 1998;28(4):731-3.
5. Gluud C, The Cochrane Hepato-Biliary Group. The Cochrane Hepato-Biliary Group: evidence based medicine for all [abstract]. Journal of Hepatology 1998;28:235.
6. Gluud C, Jørgensen T, Koretz RL, Morabito A, Pagliaro T, Sutton R. The Cochrane Hepato-Biliary Group: evidence based medicine for all [abstract]. Journal of Gastroenterology and Hepatology 1998;13:A20.
7. Nikolova D, Gluud C. CHBG Newsletter 1998;2(1):1-4.

**Publications in 1997**

1. Nikolova D, Gluud C. CHBG Newsletter 1997;1:1-4.